/
Metabolic & Endocrine
Obesity
177
Pipeline Programs↗
446
Active Trials↗
122
Companies Involved↗
Obesity is a highly competitive landscape with 177 programs across 122 companies. The most active players are Eli Lilly, Novo Nordisk, Regeneron. 37 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical75
Phase 141
Phase 224
Phase 337
Approved
No programs
Analysis
Modality Breakdown
84%
Small molecule
116 of 138 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 138 classified programs, each share of the total. Modality classified for 80% of 177 pipeline programs.
Analysis
Trial Status
875
clinical trials
Completed360 · 41%
Recruiting216 · 25%
Active, not recruiting110 · 13%
Not yet recruiting100 · 11%
Terminated23 · 3%
Unknown status23 · 3%
Other43 · 5%
Clinical Trials
Trial Activity
875 trials
Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation &Amp;Amp;Amp;Amp; Metabolic Rate
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Preclinical·NCT06044935·100 enrolled
Page 1 of 59
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)